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Abstract 
Background: Although targeted therapies have improved the clinical outcomes of cancer treatment, tumors resist‑
ance to targeted drug are often detected too late and cause mortality. CSE1L is secreted from tumor and its phospho‑
rylation is regulated by ERK1/2. ERK1/2 is located downstream of various growth factor receptors and kinases, the tar‑
gets of most targeted drugs. Serum phospho‑CSE1L may be a marker for monitoring the efficacy of targeted therapy.
Methods: We used mice tumor xenograft model to study the assay of serum phosphorylated CSE1L for early detect‑
ing the efficacy of targeted drugs. The phosphorylation status of CSE1L in vemurafenib and sorafenib treated tumor 
cells were assayed by immunoblotting with antibody against phosphorylated CSE1L.
Results: Ras activation increased phospho‑CSE1L expression in B16F10 melanoma cells. Vemurafenib and sorafenib 
treatment did not significantly reduce the total CSE1L levels; however, they inhibited ERK1/2 and CSE1L phosphoryla‑
tion in A375 melanoma cells and HT‑29 colorectal cancer cells. In the melanoma xenograft model, serum phospho‑
CSE1L level declined 5 days after vemurafenib/sunitinib treatment and 3 days after sorafenib/lapatinib treatment in 
the HT‑29 colon cancer xenograft model. Vemurafenib/sunitinib and sorafenib/lapatinib treatments resulted in tumor 
regression.
Conclusions: Our results indicated that serum phospho‑CSE1L is useful for early detecting the efficacy of targeted 
therapy in initial treatment and for monitoring emerging secondary drug resistance to facilitate timely therapeutic 
decision making.
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Background
Compared with empirical chemotherapy, targeted ther-
apy yields substantially improved clinical outcomes 
in cancer treatment. However, the efficacy of targeted 
therapies in cancer patients is often limited by the emer-
gence of resistance. For example, the response rate was 
approximately 50% for vemurafenib in melanoma with 
B-Raf V600E mutation [1]. Moreover, numerous patients 
eventually developed resistance to the drugs within 
1  year of treatment, despite successful initial treatment 
[2]. Another example is that the response rate of Cetuxi-
mab monotherapy was 11%, and was 23% in combina-
tion with irinotecan for colorectal cancer treatment [3]. 
The progression of a tumor may be rapid, and tumor 
resistance to a targeted drug is often detected too late. 
Therefore, it is essential to assess the efficacy of targeted 
therapy in initial treatment and monitor the develop-
ment of resistance to the targeted drug after a successful 
initial treatment.
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The Ras-Raf-MAPK-ERK signaling cascade as well as 
its upstream growth factor receptors are frequently acti-
vated in cancer and are the targets of most targeted drugs 
[4–7]. For example, vemurafenib (PLX4032, RG7204) 
is a potent inhibitor of B-Raf V600E in melanoma treat-
ment [8]. Sorafenib (BAY 43-9006) is a multi-kinase 
inhibitor of Raf-1, B-Raf, and vascular endothelial cell 
growth factor receptor-2 (VEGFR-2) [9]. Sorafenib inhib-
its the phosphorylation of mitogen-activated protein 
kinase (MAPK) and extracellular signal-regulated kinase 
(ERK1/2) in various cancer cell lines and tumor xeno-
grafts [10–12]. Sunitinib malate (Sutent, SU11248; Pfizer 
Inc.) is a multi-targeted receptor tyrosine kinase (RTK) 
inhibitor of VEGFRs, platelet-derived growth factor 
receptors (PDGFRs), SCF receptor (c-kit), and FLT3 [13–
15]. Lapatinib, a potent human epidermal growth factor 
receptor 2 (HER2) and epidermal growth factor receptor 
(EGFR) inhibitor, is an oral drug for breast cancer and 
other solid tumors [16, 17]. ERK1/2 is located down-
stream of the Raf/MEK/ERK (MAPK) signal transduction 
cascade, at which cancer signaling from various upstream 
growth factor receptors, such as ErbB/HER, VEGFR, 
PDGFR, c-kit, and hepatocyte growth factor receptor 
(Met), and from Ras, Raf, and MAPK/ERK kinase (MEK) 
signaling converge [4–7, 18–23]. All of these receptors 
and kinases are potential targets for drugs designed for 
cancer therapy. Therefore, the activity of ERK1/2 in tar-
geted drug-treated tumor can indicate the efficacy of the 
drug. It is difficult to obtain tumor tissue through biopsy 
to assay the ERK1/2 activity in a tumor in clinical setting. 
Biomarkers that are linked with ERK1/2 signaling and 
are secreted from tumor may be excellent markers for 
assessing tumor responses to a targeted drug, and thus 
can be used in early detection of the efficacy of a targeted 
therapy.
The chromosome segregation 1-like (CSE1L) protein is 
the human homologue of CSE1, the yeast chromosome 
segregation protein [24]. Pathological studies have shown 
that CSE1L is highly expressed in most cancer types, and 
its expression is associated with advanced cancer stage 
and poor outcome in cancer patients [25–27]. We have 
previously reported that CSE1L is a secretory protein 
present in the sera of cancer patients [28–30]. Our previ-
ous studies have shown that CSE1L is a phosphorylated 
protein, and its phosphorylation is regulated by Ras-ERK 
signaling [31, 32]. We studied serum phospho-CSE1L for 
assaying the efficacy of targeted therapy using mice mela-
noma and colorectal tumor xenograft models and drugs 
including vemurafenib, sorafenib, sunitinib, and lapat-
inib. Here, we report that serum phospho-CSE1L can be 
used to monitor the efficacy of targeted drugs as early as 
3  days after drug administration. The results suggested 
that serum phospho-CSE1L has clinical application in 
early detecting the development of resistance to targeted 
drugs to improve the cure rate of cancer.
Methods
Antibodies, targeted drugs, and reagents
The antibodies used in the experiment were anti-p21/
ras (EP1125Y) (Epitomics, Burlingame, CA, USA); anti-
CSE1L (3D8) and anti-phospho-ERK1/2 (phospho 
T202/204, G15-B) (Abnova, Taipei, Taiwan); anti-β-actin 
(Ab-5) (Lab Vision, Fremont, CA, USA); anti-CSE1L 
(24) and anti-CSE1L (H2) (Santa Cruz Biotechnology, 
Santa Cruz, CA, USA). PD98059 and other reagents were 
obtained from Sigma (St. Louis, MO, USA).
The targeted drugs used in the experiment were vemu-
rafenib (Selleck South Loop West, TX, USA), sorafenib 
tosylate (Santa Cruz Biotechnology), sunitinib (Pfizer 
Inc., New York, NY, USA), and lapatinib ditosylate 
(Tykerb) (GlaxoSmithKline plc, Brentford, England).
Cells and cell cultures
A375 human melanoma cells were obtained from the 
American Type Culture Collection (Manassas, VA, USA). 
NIH 3T3 mouse embryo fibroblast cells, human foreskin 
fibroblast cells, HT-29 colorectal cancer cells, and B16F10 
mouse melanoma cells were maintained in our labora-
tory previously [31–33]. Cells were cultured in Dulbec-
co’s modified Eagle’s medium (DMEM) supplemented 
with 10% heat-inactivated fetal bovine serum (FBS), 100 
units/mL of penicillin, 100 mg/mL of streptomycin, and 
2 mmol/L of glutamate at 37°C in a humidified 5% CO2 
atmosphere. B16F10 melanoma cells expressing v-H-Ras 
expression vectors (i.e. the B16-Ras cells), CSE1L expres-
sion vectors (i.e. the B16-CSE1L cells), and the control 
vectors (i.e. the B16-dEV cells) were established previ-
ously [31].
Production of antibodies specific to phosphorylated CSE1L
Phosphopeptide, LTpEYpLKKTLDPDPAC (Tp denotes 
phospho-threonine and Yp denotes phospho-tyrosine), 
and non-phosphopeptide, LTEYLKKTLDPDPAC, were 
synthesized using the solid-phase method. The phospho-
rylated peptides were conjugated through the N-termi-
nal cysteine thiol to keyhole limpet hemocyanin (KLH). 
New Zealand rabbits were immunized with the peptides 
five times. The immunized serum was collected a week 
after the final immunization. IgG fractions were puri-
fied using a protein G column (Amersham Pharmacia 
Biotech, Uppsala, Sweden). The antibodies were puri-
fied using a phosphorylated peptide affinity column 
followed by non-phosphopeptide cross-adsorption to 
remove non-phospho-specific antibodies. The titer and 
the specificity of the antibodies were tested by ELISA and 
immunoblotting.
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Immunoblotting
All cell lysates were prepared using lysis buffer contain-
ing phosphatase inhibitors unless otherwise indicated. 
Cells were washed with phosphate-buffered saline 
(PBS) and lysed in ice-cold radioimmunoprecipita-
tion assay (RIPA) buffer (25  mM Tris–HCl [pH 7.2], 
0.1% SDS, 0.1% Triton X-100, 1% sodium deoxycho-
late, 150 mM NaCl, 1 mM EDTA, 5 mM sodium ortho-
vanadate, 1  mM phenylmethylsulfonyl fluoride, 10 μg/
mL of aprotinin, and 5  μg/mL of leupeptin) contain-
ing phosphatase inhibitors (25 mM β-glycerophosphate 
and 5 mM sodium fluoride). The protein concentrations 
were determined using a BCA protein assay kit (Pierce, 
Rockford, IL, USA). Protein samples (50 μg each) were 
loaded onto an SDS–polyacrylamide gel. Proteins were 
transferred to nitrocellulose membranes (Amersham 
Pharmacia, Little Chalfont, Buckinghamshire, UK). 
The membrane was incubated with blocking buffer (1% 
bovine serum albumin [BSA], 50  mM Tris–HCl [pH 
7.6], 150  mM NaCl, and 0.1% Tween-20) for 1  h. The 
blots were reacted with primary antibodies at 4°C and 
incubated overnight; subsequently, they were incubated 
with secondary antibodies conjugated to horserad-
ish peroxidase (HRP) for 1  h. The protein levels were 
detected by enhanced chemiluminescence by using a 
Forte Western HRP substrate (Millipore, Billerica, MA, 
USA).
Immunofluorescence
Cells grown on coverslips (12 × 12 mm) were cytospun 
at 1,000 rpm for 10 min. The cells were washed with PBS, 
fixed with 4% paraformaldehyde, permeabilized with 
methanol, and blocked with PBS containing 0.1% BSA. 
The cells were then incubated with primary antibod-
ies for 1 h, washed with PBS three times, and incubated 
with goat anti-mouse IgG secondary antibodies coupled 
to Alexa Fluor 488. Subsequently, the cells were exam-
ined using a Zeiss Axiovert 200 M inverted fluorescence 
microscope (Carl Zeiss, Jena, Germany). Experiments 
were performed on duplicate coverslips, and ten random 
fields were photographed per coverslip.
Protein phosphatase treatment
For protein phosphatase treatment, cells were washed 
with PBS and lysed in phosphatase-inhibitor-depleted 
RIPA buffer (25 mM Tris–HCl [pH 7.2], 0.1% SDS, 0.1% 
Triton X-100, 1% sodium deoxycholate, 150  mM NaCl, 
1 mM phenylmethylsulfonyl fluoride, 10 μg/mL of apro-
tinin, and 5 μg/mL of leupeptin) at 4°C. The cell lysate 
was incubated with protein phosphatase reaction buffer 
containing 50 mM HEPES (pH 7.5), 10 mM NaCl, 2 mM 
DTT, 0.01% Brij 35, 1  mM MnCl2, and 4,000 units of 
lambda protein phosphatase (New England Biolabs, 
Ipswich, MA, USA) in a total volume of 100 μL at 30°C 
for 1 h.
DNA fragmentation assay
Cells cultured in cultured medium containing 10% FBS 
were treated with vemurafenib for 96  h. The detached 
cells in media and attached cells harvested with trypsin–
EDTA digestion were combined and centrifuged at 
1,000g for l0 min. The cell pellets were incubated in lysis 
buffer (50  mM Tris–HCl [pH 8.0], 10  mM EDTA, 0.5% 
sarkosyl, 0.5 mg/mL of proteinase K) at 50°C for 1.5 h and 
then treated with 0.5 μg/mL of RNase A for 30 min. The 
DNA was extracted using phenol–chloroform-isoamyl 
alcohol and analyzed by gel electrophoresis (1.8% aga-
rose gel) with ethidium bromide staining. The amount of 
DNA loaded in each well was 20 μg.
Animal targeted therapy model
Male NOD SCID mice (8  weeks of age; National Labo-
ratory Animal Center, Taipei, Taiwan) were housed in a 
clean room and maintained in sterilized filter-topped 
cages equipped with high-efficiency particulate air 
(HEPA) filter-ventilated racks. The mice received sterile 
rodent chow and water ad libitum. Each mouse was sub-
cutaneously inoculated with viable cancer cells (1 × 104 
cells in 100 μL of PBS/mouse) in the dorsal skin by using 
a 26-gauge needle.
Vemurafenib (75  mg/kg) and sunitinib (20  mg/kg) 
were dissolved in dimethyl sulfoxide (DMSO) and sus-
pended in an aqueous vehicle solution containing 2% 
hydroxypropyl cellulose (Sigma) in PBS; this mixture 
was adjusted to pH 4 by using dilute HCl. Sorafenib 
(80  mg/kg) and lapatinib (60  mg/kg) were suspended 
in an aqueous vehicle solution containing 2% hydroxy-
propyl cellulose in PBS, and the mixture was adjusted 
to pH 4 by using dilute HCl. For the control groups, 
lapatinib (1 mg/kg) was suspended in an aqueous vehi-
cle containing 2% hydroxypropyl cellulose in PBS, and 
the mixture was adjusted to pH 4 by using dilute HCl. 
When the tumors attained a volume of approximately 
100–150  mm3, each mouse was labeled using a mouse 
ear punch. Each mouse was then weighed, and blood 
(approximately 200  μL) was extracted from the facial 
vein by using a lancet. The mice were divided into two 
groups, and each group had mice bearing tumors of 
similar sizes. Beginning on the next day, the mice were 
fed with the targeted drugs (in a volume of 100  μL) 
through oral gavage by using a feeding needle (gavage 
needle) daily for 10  days. Mice were fed with vemu-
rafenib and sunitinib (for A375 melanoma cells-injected 
mice), sorafenib and lapatinib (for HT-29 colorectal can-
cer cells-injected mice), or lapatinib (1 mg/kg) (for the 
control groups). Vemurafenib may work in melanoma 
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patients whose tumor has a B-Raf V600E mutation, and 
A375 melanoma cells harbor the mutation [34]. Lapa-
tinib was reported to be unable to prevent the growth 
of A375 melanoma cells [35]. HT-29 cancer cells carry 
B-Raf mutation [36]. K-Ras/B-Raf mutations are associ-
ated with resistance to lapatinib, and the HT-29 colo-
rectal cancer cell line was reported to be resistant to 
lapatinib [37]. The group of mice injected with HT-29 
colorectal cancer cells consisted of 15 mice, the group of 
mice injected with A375 melanoma cells consisted of 10 
mice, and each control group consisted of five mice. The 
tumor size of each mouse was measured using a size 
caliper every 2 days. Blood (about 200 μL) was collected 
from each mouse injected with HT-29 cells 3 days post 
the first day of drug administration, and 5 days post the 
first day of drug administration for mouse injected with 
A375 melanoma cells. Serum samples were collected by 
allowing blood to stand at room temperature for a mini-
mum of 30 min to allow clots to form. The blood sam-
ples were centrifuged at 2,000g for 10 min, and the sera 
in supernatants were subsequently harvested and stored 
at −80°C. The tumor volume (cm3) was calculated using 
the following formula: W2 ×  L ×  0.5, where W is the 
width (small diameter) and L is the length (large diam-
eter) of the tumor measured in centimeters. Mouse care 
and experimental procedures were performed accord-
ing to the guidelines of the Animal Care Committee of 
the Taipei Medical University, Taiwan.
ELISA
Anti-CSE1L (H2) antibody-coated 96-well plates (Costar) 
were blocked with 5% BSA in TBS (Tris-buffered saline) 
for 1 h. The wells were washed with TBST (0.05% Tween 
20 in TBS) and then incubated with serum samples (six-
fold dilution with TBS) for 1 h. After being washed with 
TBST, the wells were incubated with biotin-conjugated 
anti-phospho-CSE1L antibodies for 1 h. The biotin-con-
jugated anti-phospho-CSE1L antibodies were prepared 
by biotinylating anti-phospho-CSE1L antibodies using 
the Biotin Labeling Kit-NH2 (Dojindo Laboratories, 
Kumamoto, Japan). The wells were then washed with 
TBST, reacted with streptavidin-conjugated horseradish 
peroxidase (R&D Systems, Minneapolis, MN, USA), and 
followed by incubation with the substrate reagent (R&D 
Systems). For calibration, two blank wells containing 
TBST were used as the background value, and two wells 
that were not coated with anti-phospho-CSE1L antibod-
ies but reacted with all other ELISA reagents were used 
as control wells. The absorbance at 450 nm was measured 
within 20 min following the reaction by using a Thermo 
Multiskan EX microplate photometer (Thermo Fisher 
Scientific, Waltham, MA, USA). Each sample was assayed 
two times.
Statistical analysis
Statistical differences were analyzed using paired t tests. 
An α level of 0.05 was used to determine statistical 
significance.
Results
Presence of hyper‑, hypo‑, and non‑phosphorylated CSE1L 
in tumor cells as analyzed by antibodies against CSE1L 
and phosphorylated CSE1L
The results of immunoblotting with the anti-CSE1L 
antibodies (clone 3D8) showed that there were three 
CSE1L protein bands with molecular weights of approx-
imately 115, 100, and 90 kDa, and the anti-CSE1L anti-
bodies mainly recognized the 100-kDa CSE1L protein 
(Figure  1a). The B16-Ras cells exhibited an increased 
115-kDa CSE1L level and decreased 100 and 90-kDa 
CSE1L levels compared with that of B16-dEV cells (Fig-
ure  1a). PD98059 is an ERK1/2 activity inhibitor, and 
PD98059-treated B16-Ras cells exhibited a decreased 
115-kDa CSE1L level and increased 100 and 90-kDa 
CSE1L levels compared with that of B16-Ras cells 
(Figure  1a). There is no commercial antibody against 
phospho-CSE1L for detecting phosphorylated CSE1L 
thus far. Therefore, we developed antibodies specific 
to phospho-CSE1L. Immunoblotting showed that Ras 
activation resulted in increased expression of phospho-
ERK1/2 (Figure  1b). Immunoblotting with cell lysates 
from B16-dEV cells and B16-Ras cells showed that the 
anti-phospho-CSE1L antibodies recognized hypo- and 
hyper-phosphorylated CSE1L proteins, and Ras acti-
vation resulted in increased expression levels of hypo- 
and hyper-phosphorylated CSE1L in B16-Ras cells 
(Figure 1b).
We studied the phosphorylation of CSE1L with lambda 
protein phosphatase which can digest the phosphoryl-
ated residue in CSE1L. The results of immunoblotting 
using lambda-protein-phosphatase-treated cell lysates, 
anti-CSE1L antibodies (clone 3D8), and anti-phospho-
CSE1L antibodies indicated that the 115-kDa protein 
was hyper-phosphorylated CSE1L, the 100-kDa protein 
was hypo-phosphorylated CSE1L, and the 90-kDa pro-
tein was non-phosphorylated CSE1L (Figure 1c). In addi-
tion, lambda protein phosphatase treatment resulted 
in decreased expression of phospho-ERK1/2 (Fig-
ure 1c). These results indicated that tumor cells express 
hyper-, hypo-, and non-phosphorylated CSE1L, and the 
anti-phospho-CSE1L antibodies recognize hyper- and 
hypo-phosphorylated CSE1L but not recognize non-
phosphorylated CSE1L.
Immunoblotting with anti-CSE1L antibodies (clone 
24) showed that hypo-phosphorylated CSE1L was 
highly expressed in HT-29 colorectal cancer cells and 
B16F10 melanoma cells and was nearly undetectable 
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in human foreskin fibroblast cells and NIH 3T3 mouse 
embryo fibroblast cells cultured under serum starvation 
(Figure 1d). Serum re-supplement resulted in increased 
hypo-phosphorylated CSE1L levels and decreased non-
phosphorylated CSE1L levels in NIH 3T3 cells (Fig-
ure 1d). These results confirmed that the 100-kDa band 
was hypo-phosphorylated CSE1L and the 90-kDa band 
was non-phosphorylated CSE1L and indicated that 
anti-CSE1L antibodies mainly recognized hypo- and 
non-phosphorylated CSE1L.
The results of immunofluorescence using anti-phos-
pho-CSE1L antibodies showed that phospho-CSE1L was 
mainly distributed in the cytoplasm of B16F10 cells (Fig-
ure  1e). In addition, the results showed the presence of 
secretory phospho-CSE1L in the extracellular vesicles 
surrounding B16-Ras cells (Figure  1e). The results indi-
cated that phospho-CSE1L is a secretory protein.
Vemurafenib and sorafenib treatment inhibited the 
phosphorylation of CSE1L and ERK1/2
We studied the effects of vemurafenib and sorafenib on 
the phosphorylation of CSE1L. A375 melanoma cells 
were treated with 1 μM vemurafenib for 24 h. The results 
of immunoblotting with anti-phospho-CSE1L antibodies 
Figure 1 Presence of hyper‑, hypo‑, and non‑phosphorylated CSE1L in tumor cells as analyzed by antibodies against CSE1L and phosphorylated 
CSE1L. a The levels of phosphorylated and non‑phosphorylated CSE1L in B16‑dEV, B16‑Ras, and PD98059‑treated B16‑Ras cells were analyzed with 
anti‑CSE1L antibody (clone 3D8) as indicated. b The levels of phospho‑CSE1L and phospho‑ERK1/2 in B16‑dEV, B16‑CSE1L, and B16‑Ras cells were 
analyzed with anti‑phospho‑CSE1L and anti‑phospho‑ERK1/2 antibodies as indicated. c Presence of hyper‑ and hypo‑phosphorylated CSE1L in B16‑
Ras cells analyzed using lambda protein phosphatase. B16‑Ras cell lysates treated with or without lambda protein phosphatase were subjected to 
immunoblotting with anti‑CSE1L (3D8), anti‑phospho‑CSE1L, and anti‑phospho‑ERK1/2 antibodies as indicated. d Presence of non‑phosphorylated 
and phosphorylated CSE1L as analyzed using serum‑starved and serum re‑fed non‑cancerous cell lines. The phosphorylation of CSE1L in cell lysates 
from serum starved or serum starved and serum retreated HT‑29 colorectal cancer cells, human foreskin fibroblast cells, NIH3T3 cells, and B16F10 
melanoma cells were analyzed using the anti‑CSE1L (clone 24) antibody. e Distribution of secretory phospho‑CSE1L in the extracellular secretion 
vesicles (arrowhead) surrounding B16‑Ras cells was analyzed by immunofluorescence with anti‑phospho‑CSE1L antibodies. Each immunoblot was 
repeated at least three times and showed similar results. The data shown here are the representative immunoblots. β‑actin levels were assayed as a 
control. pp-CSE1L hyper‑phosphorylated CSE1L, p-CSE1L hypo‑phosphorylated CSE1L, non-p-CSE1L non‑phosphorylated CSE1L.
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showed that vemurafenib treatment, compared with 
treatment with the vehicle solution (DMSO), reduced 
the hyper-phosphorylated CSE1L level and inhibited the 
phosphorylation of ERK1/2 in A375 cells (Figure  2a). 
Although vemurafenib treatment reduced hypo-phos-
phorylated CSE1L levels, the decrease was not signifi-
cant. Because the anti-CSE1L antibodies reacted more 
strongly with hypo-phosphorylated CSE1L than with 
hyper-phosphorylated CSE1L, immunoblotting with the 
anti-CSE1L antibodies showed that vemurafenib treat-
ment did not significantly reduce the total CSE1L level 
(Figure  2a). Thus, anti-phospho-CSE1L antibody was 
much more useful than anti-CSE1L antibody in deter-
mining the variation in the phosphorylation status of 
CSE1L induced by vemurafenib (Figure 2a). Vemurafenib 
treatment also induced apoptotic body formation and 
DNA fragmentation in A375 melanoma cells in a longer 
treatment time (72 h) (Figure 2b, c). Since the phospho-
rylation of CSE1L is regulated by ERK1/2, these results 
indicated that vemurafenib inhibited ERK1/2 phospho-
rylation and reduced the level of CSE1L phosphorylation.
HT-29 colorectal cancer cells were treated with 6  μM 
sorafenib for 24 h. The results of immunoblotting showed 
that sorafenib treatment inhibited ERK1/2 phosphoryla-
tion in HT-29 cells (Figure 3a). The results of immunob-
lotting with anti-phospho-CSE1L antibodies showed that 
sorafenib treatment resulted in the decline in the hyper- 
and hypo-phosphorylated CSE1L levels (Figure  3a). The 
results of immunoblotting showed that anti-phospho-
CSE1L antibody was more useful than anti-CSE1L anti-
body in determining the variation in the phosphorylation 
status of CSE1L induced by sorafenib (Figure 3a). Sorafenib 
treatment also inhibited the proliferation of HT-29 cells by 
30% in a longer treatment time (96 h) (Figure 3b).
Serum phospho‑CSE1L level declined 
following vemurafenib and sunitinib treatment in mice 
inoculated with human melanoma xenografts
We used mice tumor xenograft model to study the assay 
of serum phospho-CSE1L for detecting the efficacy of 
targeted drugs. NOD SCID mice bearing tumors derived 
from A375 human melanoma cells were fed daily with 
75  mg/kg of vemurafenib and 20  mg/kg of sunitinib or 
an ineffective prescription of targeted treatment, 1  mg/
kg of lapatinib, for 10  days. The results showed that 
Figure 2 Vemurafenib treatment inhibits the phosphorylation of 
CSE1L and ERK1/2. a Vemurafenib treatment inhibited the phospho‑
rylation of ERK1/2 and CSE1L. The levels of hyper‑phosphorylated 
CSE1L, hypo‑phosphorylated CSE1L, and phospho‑ERK1/2 in A375 
melanoma cells treated with or without 1 μM vemurafenib for 24 h 
were subjected to immunoblotting with anti‑CSE1L (clone 3D8), 
anti‑phospho‑CSE1L, and anti‑phospho‑ERK1/2 antibodies. β‑actin 
levels were assayed as a control. b A representative image shows 
vemurafenib‑induced apoptotic body formation in A375 melanoma 
cells. Cells were treated with or without 1 μM vemurafenib for 72 h. c 
DNA fragmentation induced by vemurafenib in A375 melanoma cells 
treated with or without 1 μM vemurafenib for 72 h. Each immunoblot 
was repeated at least three times and showed similar results. The data 
shown here are the representative immunoblots.
Figure 3 Sorafenib treatment inhibits the phosphorylation of CSE1L 
and ERK1/2. a Sorafenib treatment inhibited the phosphorylation of 
ERK1/2 and CSE1L. The levels of hyper‑phosphorylated CSE1L, hypo‑
phosphorylated CSE1L, and phospho‑ERK1/2 in HT‑29 colorectal 
cancer cells treated with or without 6 μM sorafenib for 24 h were 
subjected to immunoblotting with anti‑CSE1L (clone 3D8), anti‑
phospho‑CSE1L, and anti‑phospho‑ERK1/2 antibodies. β‑actin levels 
were assayed as a control. Each immunoblot was repeated at least 
three times and showed similar results. The data shown here are the 
representative immunoblots. b The cell numbers of HT‑29 colorectal 
cancer cells treated with or without 6 μM sorafenib for 96 h were 
counted using trypan blue exclusion assays. The graph summarizes 
the results of three independent assays.
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vemurafenib and sunitinib treatment significantly inhib-
ited the growth of melanoma xenografts derived from 
A375 cells, even when treatment was initiated until the 
tumors were quite large. On the basis of caliper measure-
ments, inhibition of tumor proliferation was observed 
on Day 6 after vemurafenib and sunitinib treatment (Fig-
ure 4a). Significant tumor regression (large area of tumor 
necrosis) was observed on Day 16 after vemurafenib and 
sunitinib treatment in all five mice (Figures 4a, 5).
In the control, mice bearing established A375 mela-
noma were fed with 1 mg/kg of lapatinib daily for 10 days. 
This study design mimics the clinical situation of targeted 
therapy in which a prescription of a targeted drug or the 
dose of a drug may be incorrect. Lapatinib treatment was 
inefficacious against melanoma xenografts derived from 
A375 melanoma cells (Figure  4b). Neither tumor stasis 
(i.e. inhibition of additional tumor growth) nor reduction 
of tumor volume occurred after lapatinib treatment in all 
four mice (five mice were used in the control group, one 
mouse died and was excluded from the study) through-
out the study period (Figure 4b).
The body weights of mice treated with vemurafenib 
and sunitinib were measured and observed to decrease 
by approximately 1  g in two mice, 2  g in one mouse, 
and 3  g in one mouse, whereas the body weight of one 
mouse increased by approximately 2.5  g (Figure  4c). In 
mice treated with 1 mg/kg of lapatinib, the body weights 
decreased by approximately 1  g in two mice and 2  g in 
two mice (Figure  4d). Because mice treated with 1  mg/
kg of lapatinib also exhibited a decrease in body weight, 
the decrease in the body weights of the mice treated with 
vemurafenib and sunitinib may not have been because 
of drug toxicity. The decrease may have resulted from 
exsanguinations in the experimental procedure.
In addition, the assay results and comparison of blood 
samples collected from mice a day prior to targeted drug 
treatment and 5  days after targeted drug treatment by 
ELISA method showed that serum phospho-CSE1L lev-
els declined 5 days after vemurafenib and sunitinib treat-
ment in all five mice, whereas serum phospho-CSE1L 
levels increased 5  days following 1  mg/kg of lapatinib 
treatment in all four mice bearing A375 melanoma xen-
ografts (Figure  5). The optical density (O.D.) values of 
serum phospho-CSE1L levels 1 day prior and 5 days after 
vemurafenib/sunitinib treatment and lapatinib treatment 
are shown in the table (Figure 5).
Figure 4 Vemurafenib and sunitinib treatment inhibits tumor growth in mice inoculated with human melanoma xenografts. Male NOD SCID mice 
bearing tumors derived from human A375 melanoma cells were fed daily with 75 mg/kg of vemurafenib and 20 mg/kg of sunitinib (a, c) or 1 mg/
kg of lapatinib, which was used as the control (b, d), for 10 days. The tumor size (a, b) and body weights (c, d) of each mouse were measured every 
2 days as indicated.
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Serum phospho‑CSE1L levels declined after sorafenib 
and lapatinib treatment in mice inoculated with human 
colorectal tumor xenografts
The assay of serum phospho-CSE1L for detecting the 
efficacy of targeted treatment was also conducted in 
the HT-29 human colorectal tumor xenograft model. 
Mice bearing established HT-29 colorectal tumors were 
administered oral doses of 80  mg/kg of sorafenib and 
60  mg/kg of lapatinib daily for 10  days. The doses of 
sorafenib and lapatinib were effective and the treatment 
significantly inhibited the growth of tumor xenografts 
derived from HT-29 cells in all 10 mice, even when drug 
treatment was initiated until the tumors were quite large. 
Decrease in tumor volume was observed on Day 4 after 
sorafenib and lapatinib treatment (Figure  6a). Complete 
tumor regression (complete tumor necrosis) occurred on 
Day 14 after sorafenib and lapatinib treatment in 3 of 10 
mice (Figures 6a, 7).
For control treatment, mice bearing established HT-29 
colorectal tumors were fed with 1  mg/kg of lapatinib 
daily for 10  days. Lapatinib was inefficacious against 
tumor xenografts derived from HT-29 colorectal cancer 
cells (Figure  6b). Caliper measurements of the tumors 
indicated that lapatinib treatment resulted in neither 
inhibition of additional tumor growth nor reduction in 
tumor size in all five mice throughout the study period 
(Figure 6b).
Following sorafenib and lapatinib treatment, the body 
weights decreased by approximately 2–3  g in four mice 
and 4 g in one mouse, and no such loss in body weight 
was observed in five mice (Figure  6c). In mice treated 
with lapatinib, the body weight decreased by approxi-
mately 0.2  g in one mouse, and no such decrease 
occurred in four mice (Figure 6d). Because the decrease 
in body weight was also observed in the control mice, 
the decreased body weight of mice treated with sorafenib 
and lapatinib may not have been because of drug toxic-
ity. The decrease in body weight may have resulted from 
exsanguinations in the study.
The assay of serum phospho-CSE1L levels in the blood 
samples collected from mice 1 day prior and 3 days after 
targeted drug treatment by ELISA method indicated 
that serum phospho-CSE1L levels declined 3  days after 
drug treatment in all 10 mice fed daily with 80 mg/kg of 
sorafenib and 60 mg/kg of lapatinib (Figure 7). The O.D. 
values of serum phospho-CSE1L levels 1  day prior and 
3 days after sorafenib and lapatinib treatment are shown 
in the table (Figure 7). In mice fed daily with 1 mg/kg of 
lapatinib, the serum phospho-CSE1L levels increased 
3  days after drug treatment in all five mice inoculated 
with HT-29 colorectal tumor xenografts (Figure  7). The 
O.D. values of serum phospho-CSE1L levels 1 day prior 
and 3 days after 1 mg/kg lapatinib treatment are shown in 
the table (Figure 7).
Discussion
Targeted therapy can substantially improve clinical out-
comes of cancer treatment and has provided cancer 
patients with new hope. However, numerous patients 
continue to experience tumor resistance to a targeted 
drug in initial treatment or after successful initial therapy 
[1–3, 38]. When the development of resistance to a tar-
geted drug is detected, tumor often has progressed; this 
leads to disease treatment more difficult and ultimately 
causing death. Detecting the change in the tumor size 
according to PET/CT (positron emission tomography-
computed tomography) scans is the main method for 
monitoring targeted therapy 2–3  months after drug 
treatment. PET/CT using fluorine-18-fluorodeoxyglu-
cose (FDG-PET/CT) can be used to evaluate glucose 
metabolism changes in tumors as early as 1  week after 
targeted drug treatment in some cancer types and some 
kinds of targeted drugs, and it plays a role in defin-
ing tumor response to targeted therapy in tumors such 
as malignant lymphoma and gastrointestinal stromal 
tumors treated with imatinib [39, 40]. However, false-
positive or equivocal results are a known limitation of 
Figure 5 Serum phospho‑CSE1L levels decline after vemurafenib 
and sunitinib treatment in mice inoculated with human melanoma 
xenografts. ELISA analysis of phospho‑CSE1L levels in serum samples 
obtained from NOD SCID mice bearing human A375 melanoma 
xenografts and fed daily with 75 mg/kg of vemurafenib plus 20 mg/
kg of sunitinib or 1 mg/kg of lapatinib as the control for 10 days. Sera 
were collected from mice 1 day prior to drug administration and 
5 days following the onset of drug administration. The ELISA assays 
were performed two times and showed similar results. The data 
shown here are representative results. The images in the lower panel 
are representative images of a mouse treated with vemurafenib/
sunitinib and showing tumor necrosis and a mouse from the control 
group 21 days after drug administration. O.D. optical density.
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FDG-PET/CT in cancer evaluation [41]. The metabolism 
of glucose is mediated by Akt (v-Akt murine thymoma 
viral oncogene)/PKB (protein kinase-B) pathway, and 
Akt is regulated by EGFR-PI3K (phosphatidylinositol-
3-kinase) signaling [42]. Accordingly, it should not be 
assumed that FDG-PET/CT can be used for assaying the 
therapeutic response of all molecular-targeted therapies. 
Therefore, using FDG-PET/CT for monitoring the tumor 
response to targeted therapy in all cancer types and all 
cancer patients is difficult. Gebhart et al. reported that, in 
86 HER2-positive breast cancer patients, only 77 patients 
had an evaluable baseline signaling using (18)F-FDG 
PET/CT scans [43]. FDG-PET/CT cannot reliably detect 
tumors <0.5 cm in size and, thus, cannot reliably detect 
emerging metastasis in tumors that acquire resistance 
to targeted drugs and undergoing metastasis [44, 45]. 
Timely monitoring of the onset of disease recurrence or 
the emergence of secondary resistance to targeted drugs 
continues to be a major challenge. Our previous study 
showed that the phosphorylation of CSE1L is regulated 
by ERK1/2 signaling, an essential signaling downstream 
of most targets in cancer cells in targeted therapy [4–7, 
31]. Our present results indicated that phosphorylated 
CSE1L is a secretory protein (Figure 1); vemurafenib and 
sorafenib treatment inhibited ERK1/2 and CSE1L phos-
phorylation (Figures  2, 3); and serum phospho-CSE1L 
levels declined 3–5 days after the administration of tar-
geted drug therapies, namely vemurafenib and sunitinib 
treatment and sorafenib and lapatinib treatment, in 
tumor xenograft models (Figures 4, 5, 6, 7). These results 
indicated that serum phospho-CSE1L is a potential 
marker for the early detection of the efficacy of targeted 
therapy.
CSE1L is highly expressed in most cancer types and it is 
a secretory protein [25–30]. By using 2D gel electropho-
resis, Scherf et  al. reported the presence of the cellular 
phosphorylated and non-phosphorylated forms of CSE1L 
[46]. Our previous study showed that healthy donor 
serum samples also contain certain levels of CSE1L, thus 
although the serum CSE1L level of cancer serum samples 
was slightly higher than that of healthy donor serum sam-
ples, the difference was not as significant as that observed 
in an assay of phosphorylated CSE1L [31]. Since CSE1L 
is also secreted from the normal cells in cancer patients, 
assay of serum phospho-CSE1L is more effective than 
that using serum CSE1L for cancer diagnosis as well as 
Figure 6 Sorafenib and lapatinib treatment inhibits tumor growth in mice inoculated with human colorectal tumor xenografts. Male NOD SCID 
mice bearing tumors derived from human HT‑29 colorectal cancer cells were fed daily with 80 mg/kg of sorafenib and 60 mg/kg of lapatinib (a, c) 
or 1 mg/kg of lapatinib as the control (b, d) for 10 days. The tumor size (a, b) and body weights (c, d) of each mouse were measured every 2 days as 
indicated.
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for the early detection of the efficacy of targeted therapy 
in patients.
Monitoring emerging secondary drug resistance is a 
crucial clinical setting in targeted cancer therapy because 
certain tumors develop resistance to targeted drugs 
after successful initial treatment. For example, tumors 
develop resistance to vemurafenib through the following 
mechanisms: tumor cells begin to overexpress PDGFR-B 
[47], N-ras mutation reactivates the normal B-Raf path-
way [47], tumors induce feedback activation of the EGF 
receptor [48], and stromal cells around tumor secrete 
hepatocyte growth factor [49]. All of these alterna-
tively activated growth factor receptors and kinases can 
reactivate MEK-ERK signaling in vemurafenib-treated 
(resistance) tumor cells, and will result in CSE1L phos-
phorylation. Thus, phospho-CSE1L is a potential bio-
marker for monitoring the emergence of secondary drug 
resistance after successful initial targeted therapy, at least 
for detecting tumor resistance to vemurafenib.
Although targeted drugs are more specific to tumors 
and do not affect the body in the same way that standard 
chemotherapeutic drugs do, targeted cancer drugs still 
cause side effects. For example, tumor blood vessel angi-
ogenesis inhibitors affect the angiogenesis of not only 
vessels located near the tumor but also those in other 
organs [50]. Thus, because of the side effects of tar-
geted drugs, the drug dose may need to be reduced in 
some clinical situations. In our study, we used an inef-
fective targeted treatment, i.e. 1 mg/kg lapatinib, as the 
control treatment, and the results indicated that this 
treatment neither caused tumor regression nor reduced 
serum phospho-CSE1L levels in the mice tumor xeno-
graft model (Figures 4, 5, 6, 7). Thus, in addition to ena-
bling early detection of the efficacy of a targeted drug 
in initial treatment and monitoring of the development 
of resistance to targeted therapy after successful initial 
treatment, assay of serum phospho-CSE1L may provide 
insight into the effect of dose reduction in the clinical 
setting and, thus, may have clinical utility in monitor-
ing the optimal dose of a drug in targeted therapy (or 
combined therapy with targeted and chemotherapeutic 
drugs).
Conclusions
Our findings suggest that serum phospho-CSE1L has 
clinical utility in the early detection of the efficacy of tar-
geted therapy as well as monitoring emerging secondary 
drug resistance in cancer patients, thus facilitating timely 
treatment decision making.
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